Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
Abstract
Human epidermal growth factor receptor 2 (HER2) targeted antibodies in combination with chemotherapy has improved outcomes of HER2 positive (pos) breast cancer (BC) but toxicity of therapy remains a problem. High levels of tumor-infiltrating lymphocytes are associated with increased pathologic complete responses for patients treated with neoadjuvant therapy. Here we sought to investigate whether delivery of intratumoral (i.t.) multiepitope major histocompatibility complex (MHC) class II HER2 peptides-pulsed type I polarized dendritic cells (HER2-DC1) in combination with anti-HER2 antibodies without chemotherapy could enhance tumor regression by increasing anti-HER2 lymphocyte infiltration into the tumor.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2022
- Source ID
- 10.1136/jitc-2022-004841
Entities
People
- Amrita Basu
- Brian J. Czerniecki
- Colin Snyder
- Corey Gallen
- Doris Wiener
- Ganesan Ramamoorthi
- Gary K. Koski
- Hongtao Zhang
- Hyo S Han
- Krithika Kodumudi
- Mark I. Greene
- Payal Grover
- Ricardo L B Costa
Organizations
- H. Lee Moffitt Cancer Center & Research Institute
- United States Department of Defense